HEALTHPAYERINTELLIGENCE

Pharmaceutical and biotech companies evaluating contract development and manufacturing organizations (CDMOs) for formulation development of...

LEARN MORE LEARN MORE LEARN MORE LEARN MORE LEARN MORE LEARN MORE LEARN MORE Formulations for Poorly Soluble & Low Bioavailability Drugs LEARN...

Ascendia Pharmaceuticals is proud to announce that it is engaged in multiple collaborations to develop and prepare injectable, inhalation, and...

The selection of a final dosage form is driven by the project’s commercial needs, and properties of the drug substance. Ascendia offers a range...

Ascendia Founder and CEO Jim Huang, Ph.D. was quoted in a new feature article on formulation trends published by Pharm Tech. The article,...

With increased water-insoluble (BCS II/IV) or low permeable (BCS III/IV) new therapeutic entities filling drug pipelines, lipid-based drug...

More than half of all approved drugs on the market contain poorly water soluble APIs. In this Formulation Forum, Ascendia CEO Jim Huang, PhD,...

Low aqueous solubility is one major problem associated with formulation development of new chemical entities, as well as for generic drug...

Contract development and manufacturing organizations (CDMOs) are focusing on providing more specialized services. That is one trend Ascendia CEO...

A growing number of pharmaceutical companies’ drug pipelines are being filled with water-insoluble (BCS II/IV) or low permeable (BCS III/IV)...